Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 02, 2015 11:00 PM ET

Pharmaceuticals

Company Overview of Ora, Inc.

Company Overview

Ora, Inc. provides clinical research and drug development services. The company offers pre-clinical research, animal toxicology studies, and compounds identification and procurement services. Additionally, it provides clinical consulting, data management, statistical analysis, and medical writing services. The company also offers strategic planning, speaker training, media planning and placement, and public relations services. Ora, Inc., formerly known as Ophthalmic Research Associates, Inc., is based in Andover, Massachusetts.

300 Brickstone Square

Andover, MA 01810

United States

Founded in 1985

Phone:

978-685-8900

Fax:

978-689-0020

Key Executives for Ora, Inc.

Chief Executive Officer and President
Senior Vice President and Chief Operating Officer
Vice President of Business Development
Director of Allergy Research
Vice President of Dry Eye Research
Compensation as of Fiscal Year 2015.

Ora, Inc. Key Developments

BioLight Life Sciences Investments Expands Relationship with Ora, Inc. to Advance the Clinical, Regulatory and Commercial Development of BioLight's TeaRx

BioLight Life Sciences Investments announced that it has expanded its relationship with Ora, Inc., via the signing of a Collaboration Agreement pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of BioLight's TeaRx multi-parameter diagnostic test for dry eye syndrome. While financial terms were not disclosed, BioLight advised that, the company and Ora will jointly fund the clinical study and other activities required to obtain USD 510,000 regulatory approval for the TeaRx multi-parameter diagnostic test for DES. BioLight also granted Ora the right to incorporate the TeaRx test in other clinical trials sponsored by third parties and performed by Ora.

Portola Pharmaceuticals Announces Collaboration with Ora, Inc. for Syk-Selective Inhibitor in Ophthalmic Diseases

Portola Pharmaceuticals announced a collaboration with Ora, Inc. for the development of Portola's highly selective Syk inhibitor, PRT2761, in ophthalmic diseases. The inhibition of Syk may more completely prevent activation of mast cells in ocular allergy and, therefore, a Syk inhibitor could represent a promising therapeutic option. This collaboration for PRT2761 is part of a strategy that allows to advance early-stage compounds outside of key focus on thrombosis and hematologic cancer with innovative companies that have the expertise and resources to develop these agents to proof-of-concept. Portola's highly specific Syk inhibitor PRT2761 has the potential to deliver rapid onset of action and comprehensive treatment of both signs and symptoms of ocular allergy, including redness, inflammation, swelling and itching.

RegeneRx's JV with G-treeBNT Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year. Each of these eye disorders was being targeted by RegeneRx prior to entering into the joint venture. Earlier clinical trials with RGN-259 (thymosin beta 4 ophthalmic solution) have demonstrated the drug candidate's ability to significantly improve both signs and symptoms of DES and identified co-primary endpoints to be targeted in the DES trials. Results of a small physician-sponsored phase 2 clinical trial in patients with severe dry eye were recently published in Cornea (2015 May;34(5):491-496) demonstrating statistically significant improvements in patients' signs and symptoms. Positive results with RGN-259 have also been seen in patients with chronic neurotrophic keratopathy, a degenerative disease of the corneal epithelium resulting from impaired corneal innervation that may cause ulceration and perforation of the cornea.

Similar Private Companies By Industry

Company Name Region
Targeted Cell Therapies LLC United States
Galderma Laboratories, L.P. United States
AbbVie Bioresearch Center Inc. United States
The Lauridsen Group, Inc. United States
AMBI Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ora, Inc., please visit www.oraclinical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.